NRIX Q3'26 Earnings: revenue estimate is 24.35M USD
Nurix Therapeutics (NRIX) will report Q3'26 earnings on October 09. Analysts estimate revenue of 24.35M USD and EPS of (0.60) USD. Details are available on the company's Financials page.
How this was made
The 30-second read
Why it matters
Traders can use the provided revenue and EPS estimates as reference points for positioning into the earnings window, but the text does not include any new company-specific developments beyond the schedule and estimates.
Market read
This is a pre-earnings calendar and estimate anchor for NRIX, relevant mainly for near-term volatility and expectation management.
What to watch
Actual impact will hinge on any company-issued guidance, pipeline updates, or one-time items that are not included here; the estimates alone may be insufficient for a directional trade.
Background
The article says Nurix Therapeutics will announce Q3'26 results on Oct. 9, with the release expected at 8:00 AM ET.
Ticker impact
Nurix Therapeutics is the subject, with Q3'26 results scheduled for Oct. 9 and a stated revenue estimate of $24.35M plus EPS of -$0.60.
Likely two-sided reaction risk around the Oct. 9 print as traders compare reported results versus the $24.35M revenue and -$0.60 EPS expectations.
The piece is a pre-earnings setup with explicit estimates but no reported results or guidance changes, so direction depends on the eventual beat or miss versus these numbers.
Market effects
Limited sector read-through because it is a single-company earnings preview with no new clinical, regulatory, or product catalyst.
Minimal, as it is not a macro release and does not describe cross-market spillovers.
Low, since the information is company-specific and does not reference global policy or cross-border events.
Counterpoint
Because the article only states expectations and timing, it may not change trading decisions versus what the market already prices in from consensus models.
Key entities
- companyNurix Therapeutics, Inc.
Subject of the earnings preview, scheduled to report Q3'26 on Oct. 9 with stated revenue and EPS expectations.
